Revolutionizing ALS Clinical Trials: A New Era Ahead

ALS research is transforming rapidly! From isolated studies to global networks, trials now boost patient access, speed up data collection, and cut timelines. Key shifts: multicenter collaborations reaching more people and adaptive designs for efficiency. Biomarkers like neurofilament light chain are game-changers—detecting changes early, as seen in tofersen’s approval. They’re integrated into trials…

Byneuroots.coDecember 2, 20250Comments

Clinical Trials News & Events

A Novel Off-the-Shelf mRNA Vaccine Enters Human Trials for Cancer Treatment

A novel mRNA therapeutic vaccine targeting cancer has progressed to clinical evaluation in humans, offering the potential to broaden therapeutic avenues across diverse tumor types through activation of the host’s innate immunity. Investigators from the University of Florida have commenced human testing of a standardized mRNA vaccine designed to engage the innate immune system, bypassing…

Byneuroots.coNovember 29, 20250Comments

Clinical Trials Neuroscience Science & Research

Regulatory Developments in Gene Therapy for Huntington’s Disease: Perspectives from uniQure’s Engagement with the U.S. Food and Drug Administration

uniQure N.V., a prominent entity in the gene therapy domain focused on developing innovative interventions for individuals with profound medical conditions, recently disclosed outcomes from a pre-Biologics License Application (BLA) interaction with the U.S. Food and Drug Administration (FDA) concerning AMT-130, an experimental adeno-associated virus-based gene therapy targeting Huntington’s disease (HD). This neurodegenerative disorder, characterized…

Byneuroots.coNovember 28, 20250Comments

Clinical Trials

Empirically Validated Insights from Peer-Reviewed Research on Repeated LSD Microdosing (as of November 28, 2025)

Recent advancements in psychedelic research have examined the therapeutic potential of repeated low-dose LSD administration, commonly termed microdosing. A pivotal investigation, representing the most extensive placebo-controlled study in major depressive disorder to date, was conducted as a Phase 2a trial by MindBio Therapeutics. This triple-blind, active-placebo-controlled design involved 89 participants randomized to receive either individually…

Byneuroots.coNovember 28, 20250Comments

A Personal View AI BNM Clinical Trials Epigenetics MND Neuroscience News & Events People & Culture Science & Research

Exclusive: Dr. Ariel Ionescu on the microRNA-126 Breakthrough That’s Giving New Hope to ALS

Ariel Ionescu, the scientist who co-founded Rinnerva Therapeutics and has spent years developing a truly innovative therapy for amyotrophic lateral sclerosis (ALS), sat down with Nicolae Tomescu. In this exclusive interview for SLA România – first published on NEUROOTS.co – Dr. Ionescu gives the straight answers to the questions that matter most to the ALS…

Byneuroots.coNovember 24, 20251Comment

Clinical Trials Herbal Therapeutics The Endocannabinoid System (ECS)

Canna Treatment Associated With Prolonged Survival in Patients With Aggressive Form of Cancer

Mahasarakham, Thailand: Patients diagnosed with cholangiocarcinoma (biliary tract cancer) who integrate cannabis into their palliative medical treatment experience prolonged survival compared to those who do not, according to the findings of a retrospective cohort study published in the scientific journal F1000 Research. Thai investigators compared survival trends among 491 patients diagnosed with advanced CCA (cholangiocarcinoma). Of these, 404 patients received palliative…

Byneuroots.coNovember 20, 20250Comments

Clinical Trials Herbal Therapeutics The Endocannabinoid System (ECS)

Cannabinoid Therapy as a Modulator of Glutamatergic–GABAergic Imbalance After Traumatic Brain Injury: A Scientifically Validated Review

Traumatic brain injury (TBI) induces a profound disruption of the excitatory–inhibitory balance through excessive glutamate release (excitotoxicity) and impaired GABAergic inhibition. Preclinical evidence, supported by multiple peer-reviewed studies, demonstrates that cannabidiol (CBD) and other cannabinoids can attenuate cortical glutamate surge, preserve or enhance GABAergic signaling, reduce neuroinflammation, and limit secondary neuronal damage. This review synthesizes…

Byneuroots.coNovember 20, 20250Comments

Clinical Trials Herbal Therapeutics The Endocannabinoid System (ECS)

Cannabinoids CBD and CBDV – A Breakthrough in the Fight Against Fungal Infections

Recent research confirms what advocates of natural medicine have claimed for years: natural cannabinoids, particularly CBD (cannabidiol) and CBDV (cannabidivarin), in their complete, unaltered plant form, possess remarkable antifungal properties. A study published on June 5, 2025, in the prestigious journal PLOS Neglected Tropical Diseases convincingly demonstrated that these natural compounds can combat a wide…

Byneuroots.coNovember 20, 20250Comments

Clinical Trials MND The Endocannabinoid System (ECS)

How CBD Enhances Exercise Endurance and the Role of Gut Bacteria

A study published in 2024 investigated how cannabidiol (CBD), a non-psychoactive compound derived from the cannabis plant, affects physical endurance in mice. Researchers observed that CBD administration made skeletal muscles more resistant to fatigue and improved mitochondrial function, the primary energy-producing structures within cells. These beneficial effects were found to depend heavily on CBD-induced changes…

Byneuroots.coNovember 20, 20250Comments